Research & Development

Aytu BioScience to acquire Innovus Pharmaceuticals

Aytu BioScience, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, announced that the companies have signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing.

Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas

Hansoh Pharmaceutical Group Company, a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.

Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK

Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK.

Mallinckrodt to divest BioVectra for £202m

UK-based biopharmaceutical company Mallinckrodt has agreed to sell its wholly-owned subsidiary BioVectra to an affiliate of H.I.G. Capital for around $250m (£202m).

Veralox Therapeutics raises $5.4m in seed funding co-led by JDRF T1D Fund and Sanofi Ventures

Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, has raised a $5.4 million seed funding round.

Sumitomo Dainippon, Roivant to create £2.4bn biopharma alliance

Japan-based Sumitomo Dainippon Pharma is set to take ownership of the stakes held by Roivant Sciences across five biopharma companies (Vants) in a deal worth $3bn (£2.43bn).

Maruho and X-Chem announce drug discovery collaboration

X-Chem has announced today a drug discovery partnership with Maruho to discover lead compounds for novel and challenging targets with applications for human diseases.

Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794.

Insilico Medicine develops AI-based drug discovery platform

US biotech company Insilico Medicine has developed a new artificial intelligence (AI) system for drug discovery, known as GENTRL.